Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
102 studies found for:    "Sclerosis" AND (woman OR women OR female)
Show Display Options
Download search resultsDownload the search results for:
"Sclerosis" AND (woman OR women OR female) (102 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS)
Conditions: Urinary Incontinence;;   Multiple Sclerosis
Intervention: Behavioral: Paula method
2 Recruiting Teriflunomide Male Transmission Study
Condition: Multiple Sclerosis
Intervention:
3 Recruiting Genes and Environment in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
4 Recruiting Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease
Conditions: Multiple Sclerosis;   Alzheimer's Disease
Intervention: Drug: [F-18]PBR06
5 Recruiting A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Conditions: Menopause;   Multiple Sclerosis
Interventions: Drug: Tissue Selective Estrogen Complex;   Drug: Placebo
6 Completed Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
7 Recruiting Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Primary-progressive Multiple Sclerosis
Interventions: Drug: estriol;   Other: Placebo;   Drug: Norethindrone;   Other: Progestin Placebo
8 Not yet recruiting A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Condition: Progressive Multiple Sclerosis
Interventions: Drug: GZ402668;   Drug: Placebo;   Drug: Acyclovir
9 Completed A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Condition: Progressive Multiple Sclerosis
Interventions: Drug: GZ402668;   Drug: placebo;   Drug: acyclovir
10 Completed Changes in Speed, Endurance and Balance in Women Patients With Multiple Sclerosis After 4 & 8 Weeks of Aquatic Exercise Training
Conditions: Multiple Sclerosis;   Aquatic;   Exercise
Interventions: Behavioral: Exercise;   Behavioral: Control
11 Completed Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
Condition: Systemic Sclerosis
Intervention: Drug: Cialis
12 Completed Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: firategrast
13 Completed Treatment of Multiple Sclerosis With Copaxone and Albuterol
Conditions: Autoimmune Diseases;   Multiple Sclerosis
Interventions: Drug: Glatiramer acetate;   Drug: Albuterol;   Drug: Albuterol placebo
14 Completed AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
Conditions: Multiple Sclerosis;   Clinically Isolated Syndrome
Intervention:
15 Terminated Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
Condition: Multiple Sclerosis (MS) - Relapsing-remitting
Intervention: Biological: sirolimus
16 Completed Safety of RG2077 in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: RG2077 (CTLA4-IgG4m)
17 Unknown  Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:
18 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
19 Withdrawn Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Condition: Multiple Sclerosis
Interventions: Drug: Rebif (IFN β-1a subcutaneous three times per week);   Drug: Tecifdera (dimethyl fumarate)
20 Recruiting EPID Multiple Sclerosis Pregnancy Study
Condition: Multiple Sclerosis
Interventions: Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG;   Drug: Extavia (interferon beta-1b), Novartis Pharma AG;   Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd;   Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd;   Drug: Avonex (interferon beta-1a), Biogen Idec Ltd;   Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046);   Other: No MSDMDs therapy (control)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.